TG Therapeutics Balance Sheet Health
Financial Health criteria checks 3/6
TG Therapeutics has a total shareholder equity of $160.5M and total debt of $100.5M, which brings its debt-to-equity ratio to 62.6%. Its total assets and total liabilities are $329.6M and $169.1M respectively. TG Therapeutics's EBIT is $20.6M making its interest coverage ratio 1.6. It has cash and short-term investments of $217.5M.
Key information
62.6%
Debt to equity ratio
US$100.48m
Debt
Interest coverage ratio | 1.6x |
Cash | US$217.51m |
Equity | US$160.50m |
Total liabilities | US$169.09m |
Total assets | US$329.59m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: NKB2's short term assets ($317.9M) exceed its short term liabilities ($53.7M).
Long Term Liabilities: NKB2's short term assets ($317.9M) exceed its long term liabilities ($115.4M).
Debt to Equity History and Analysis
Debt Level: NKB2 has more cash than its total debt.
Reducing Debt: NKB2's debt to equity ratio has increased from 0.3% to 62.6% over the past 5 years.
Debt Coverage: NKB2's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: NKB2's interest payments on its debt are not well covered by EBIT (1.6x coverage).